Next Phase Newsletter

A family office founded by a successful medical device entrepreneur can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Heathcare IT, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology, Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital branch of a drug retailing chain looks to make strategic equity investments into companies of up to $5 million. The firm is generally stage agnostic although they prefer companies at or near commercialization. The firm is actively reviewing new investment opportunities and is open to consider companies from around the globe.

The firm is focused on investing in companies of mutual strategic benefit to the parent company. This includes companies in sectors of Medical Devices, Point of Care Diagnostics, Healthcare Services, Pharmacy Innovation, and Sensors/Wearable devices. For medical devices and diagnostics the company prefers products that are near or have reached commercialization as the firm can add significant strategic value in distribution, marketing and sales. The firm is also very interested in products that will be sold directly to patients or devices/diagnostics that will be able to be used in the firms’ clinics. For wearable devices and sensors the firm is most interest in technologies with clinical value in terms of disease treatment and/or management.  The firm is open to all indication types.

The firm is looking for privately held companies with experienced management teams. The firm looks to take a board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital fund of a large insurance provider is looking to make private investments in the healthcare space ranging from $5 – $15 million in stages ranging anywhere from seed to buyout. The firm looks to invest in companies of strategic interest to its parent also seeking strong financial returns. The firm is willing to look at opportunities around the globe.

Within the Healthcare the firm is looking to invest in sectors of Healthcare IT, Services, and Diagnostics and to a lesser extent wearable devices. The firm is most interested in companies that are have reached or are very near FDA approval and are targeting large market indications.

The firm is looking for companies with experienced management teams and prefer working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A private investment firm that was formed in 2001 to manage the capital of a successful entrepreneur and a concentrated, select group of other individuals and institutions is seeking to invest into privately held companies in the life science space. Because of the firm’s capital base, they have the ability to be highly flexible and move quickly with investment opportunities. The firm is currently focused on acquiring or investing in outstanding companies, co-investing with debt or equity sponsors, and committing capital to established third-party managers in the private and public markets. The firm can be flexible in terms of investment size and is open to reviewing opportunities from around the globe.

Within the Life Science space, the firm is primarily focused on companies in the healthcare and pharmaceutical services space where the firm has significant experience and expertise. That being said the firm is also open to reviewing early stage companies developing therapeutics, medical device, diagnostics and laboratory equipment. The firm is opportunistic across technology types and indications for these opportunities and will consider companies with products in pre-clinical stage of development to those that already have a product on the market.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global pharmaceutical company is looking to form partnerships with small biotech companies using a variety of structures depending on the needs of the opportunity, including licensing, development partnerships, co-marketing, and acquisitions.  Partnerships may also involve in-kind services.  The firm works with partners worldwide.

The firm is currently looking opportunistically at novel therapeutic assets.  While the firm will consider assets in any indication area, immuno-oncology is an area of high interest; the firm is also particularly interested in other areas of immunology and in inflammation, metabolic disease (particularly type 2 diabetes), fibrosis and hypertension. The firm is open to any type of modality, including small molecules, biologics or cell therapies. The firm also has some interest in companion diagnostics and means of selecting suitable patients or monitoring patients. The firm will work with companies at any stage of development, from very early discoveries through to market.

The firm does not work with companies pursuing incremental innovations; the firm only partners on novel, breakthrough technologies, such as new molecules or new targets. The firm is interested in assets in which the mechanism of action is understood, and it is preferred that the target or pathway of the asset is validated. The firm is interested in assets that have been shown to have an unambiguous advantage, and which can create value for patients and payers.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A US based Venture Capital firm is currently looking to make investments from a $125 million with up to 20% of the committed capital going to seed and early stage companies and projects. The firm typically invests between $2 and $4 million initially and $6 million to 10$ million over the lifetime of the investment. Investments are generally in the form of milestone based equity tranches, however the firm also has experience in working with convertible notes. The firm is looking to make 4-6 allocation in the next 6-9 months throughout the United States however they are focused on companies in the Southeast.

The firm is currently looking for early stage companies in the Therapeutics, Diagnostics, Medical Technology and HealthCare IT spaces. In the Therapeutics space the firm is opportunistic in terms of subsector but is most interested in indications of Ophthalmology, Cardiovascular, Pulmonary, Anti-Infectives, Metabolic Disorders, Renal Diseases, Oncology, Immunology, Dermatology, and Orphan Diseases. For companies developing therapeutics the firm is looking for companies primarily with a lead product in preclinical trials although they will consider companies with products having recently entered Phase I. The firm also has generally stayed away from and is not currently seeking companies working with Regenerative Medicine and Wound Care.  In the Medical Technology space the firm strongly prefers that the company have at least have an early prototype of their product and the firm is opportunistic in terms of device subsector.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family office based in the US is interested in therapeutic, diagnostic, medical device, or healthcare IT companies located throughout the Mid-west. The firm is looking to make 5 more allocations this year with the average investment size around $1 million dollars.

The firm is interested in early stage therapeutics and generally participates in Series A and Series B rounds. The firm will also consider PMA, 510K, and software enabled medical devices in the development, clinical, or on the market stage. The firm does not have a revenue requirement. The firm will also consider healthcare IT, lab equipment, and drug development enabling tech. The firm will invest in orphan diseases, depending on the opportunity, but it is not their primary concern. There are no specific indications of interest.

The firm takes a hands on approach to investing and looks for an experienced, knowledgeable management team that is easy to work with and open to advice.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com